As the U.S. stock market faces heightened volatility amid escalating trade tensions and economic uncertainty, major indices like the Dow Jones and Nasdaq have entered correction and bear market ...

The acquisition also advances Lantheus’ capabilities with the addition of Evergreen’s radioligand therapy manufacturing infrastructure, including a revenue-generating CDMO business. “Today marks a ...

Evergreen is a clinical-stage radiop Enhances Lantheus’ growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for ...

Evergreen is a clinical-stage radiop Enhances Lantheus’ growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for ...

Lantheus Holdings Inc develops diagnostic products for the healthcare sector. Its chief product is imaging agents used by physicians in diagnostic procedures such as cardiac ultrasounds and X-ray ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Evergreen Seniors Community Centre is operated by the City of Guelph Recreation Department and is a member of the Older Adult Centres Association of Ontario (OACAO). To view the Evergreen Seniors ...

Analysts raise price forecasts. Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio Lantheus strengthens its radiopharmaceutical ...

Newbuild prices have soared in the 2020s, one of the most profitable decades for shipping. As an example, Evergreen’s latest deal works out at more than $100m more per ship compared to the $164m ...

Recent Acquisition Announcements Lantheus anticipates adding two more commercial therapies, with the pending acquisitions of Life Molecular Imaging and Evergreen Theragnostics, both of which are ...